Oddity Tech has demonstrated the viability of its direct-to-consumer business model through two flagship beauty brands that collectively generated over $550 million in revenue in 2025. The company’s online and mobile sales channels contributed more than 65% of total revenue last year, with repeat-purchase rates climbing from 28% in 2023 to 36% in 2025. This improvement reflects successful loyalty initiatives and targeted promotions that have shortened the payback period on customer-acquisition costs by 15% year-over-year.

By leveraging behavioral and purchase data, Oddity Tech has refined its product development pipeline and marketing outreach. Internal analytics now guide the launch of new SKUs, resulting in a 42% success rate for products hitting $1 million in first-year sales—up from 30% two years ago. The company reinvests 20% of gross profit back into AI and machine-learning tools that optimize pricing, inventory allocation, and personalized customer recommendations.

In November 2025, Oddity introduced Methodiq, a telehealth service addressing acne, hyperpigmentation, and eczema with AI-powered skin analysis and over 100 personalized treatment plans. Early trials have enrolled more than 12,000 users, and management expects Methodiq to contribute $75 million in incremental revenue by year-end 2026. Backed by 28 proprietary formulations developed by its biotech subsidiary, Oddity Labs, the platform targets a total addressable market of over $15 billion across dermatology care and prescription-adjacent treatments.

The Voyager Portfolio’s decision to include Oddity Tech underscores growing investor conviction in the company’s long-term outlook. Portfolio managers cited Oddity’s 24% compound annual growth rate in revenue from 2022 through 2025 and a sustained adjusted operating margin above 18% as key factors. They anticipate that further brand rollouts and the scaling of Methodiq could lift annual revenue past $1 billion by 2027, solidifying Oddity’s position as a leader in beauty-tech innovation.